Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12404534 | 0.84 | ALDH1A1 (0.50) | ALDH1A1TSHRTDP1 | |
| SCHEMBL49039 | 0.80 | — | — | |
| SCHEMBL12619161 | 0.78 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL5190786 | 0.78 | ALDH1A1 (0.35) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27895817 | 0.76 | — | — | |
| SCHEMBL29989468 | 0.76 | — | — | |
| SCHEMBL13916841 | 0.75 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL19050211 | 0.75 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL27319909 | 0.73 | ALDH1A1 (0.46) | ALDH1A1TSHRTDP1 | |
| Methyl Alcohol SCHEMBL6261246 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 609 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025053792-A1 | COLLECTIVE SYNTHESIS OF PHANTOMOLIN FAMILY THROUGH TOTAL SYNTHESIS OF THE SESQUITERPENE LACTONE MOLEPHANTIN | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-03-13 | — | — | WO | claimed |
| US-20160185717-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2016-06-30 | — | — | US | claimed |
| WO-2015000825-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2015-01-08 | — | — | WO | claimed |
| EP-2821394-A1 | Compounds with antibacterial activity | Fundacion MEDINA. Centro de Excelencia en Investigacion de Medicamentos Innovadores en Andalucia (ES) | 2015-01-07 | — | — | EP | claimed |
| US-20140243517-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | ASTRAZENECA AB (SE) | 2014-08-28 | — | — | US | claimed |
| US-20110201795-A1 | Methods of Producing C-Aryl Glucoside SGLT2 Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-08-18 | — | — | US | claimed |
| EP-1979362-B1 | NOVEL SILANE COMPOUNDS AND USE THEREOF IN ORDER TO FUNCTIONALISE SOLID MEDIA AND IMMOBILISE BIOLOGICAL MOLECULES ON SAID MEDIA | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2010-12-15 | — | — | EP | claimed |
| US-20090005269-A1 | Novel Silane Compounds and Their Use in Functionalizing Solid Supports and Immobilizing Biological Molecules on These Supports | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-01-01 | — | — | US | claimed |
| EP-1979362-A1 | NOVEL SILANE COMPOUNDS AND USE THEREOF IN ORDER TO FUNCTIONALISE SOLID MEDIA AND IMMOBILISE BIOLOGICAL MOLECULES ON SAID MEDIA | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2008-10-15 | — | — | EP | claimed |
| US-7419653-B2 | Method for preparing radiolabeled thymidine having low chromophoric byproducts | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2008-09-02 | — | — | US | claimed |
| WO-2005058247-A2 | METHOD FOR PREPARING RADIOLABELED THYMIDINE HAVING LOW CHROMOPHORIC BYPRODUCTS | MOLECULAR TECHNOLOGIES, INC. (US) | 2005-06-30 | — | — | WO | claimed |
| US-20050131223-A1 | Method for preparing radiolabeled thymidine having low chromophoric byproducts | CTI PET SYSTEMS, INC. | 2005-06-16 | — | — | US | claimed |
| US-20050131224-A1 | Method for preparing radiolabeled thymidine | CTI PET SYSTEMS, INC. | 2005-06-16 | — | — | US | claimed |
| WO-2004063209-A2 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-29 | — | — | WO | claimed |
| WO-2004060406-A2 | POLYMERIC REAGENTS COMPRISING A KETONE OR A RELATED FUNCTIONAL GROUP | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2004-07-22 | — | — | WO | claimed |
| US-20040138439-A1 | inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example 1-C-(substituted diphenylmethane-3-yl)- beta -D-glucopyranose | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | claimed |
| EP-0600161-A1 | Amino acid terminated polyesters having predetermined monomeric sequence | United States Surgical Corporation (US) | 1994-06-08 | — | — | EP | claimed |
| EP-0579173-A2 | Polyesters having predeterminated monomeric sequence | United States Surgical Corporation (US) | 1994-01-19 | — | — | EP | claimed |
| US-5256762-A | Polyesters having predetermined monomeric sequence | UNITED STATES SURGICAL CORPORATION (US) | 1993-10-26 | — | — | US | claimed |
| US-5248761-A | Amino acid terminated polyesters having predetermined monomeric sequence | UNITED STATES SURGICAL CORPORATION (US) | 1993-09-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005269-A1 | Novel Silane Compounds and Their Use in Functionalizing Solid Supports and Immobilizing Biological Molecules on These Supports | SELE, ELANE, EPCAM | ALDH1A1 374/4885TSHR 3246/4885TDP1 4430/4885 |
| US-20050131223-A1 | Method for preparing radiolabeled thymidine having low chromophoric byproducts | TYMP, TYMS, FLT1 | ALDH1A1 1360/4885TSHR 493/4885TDP1 226/4885 |
| US-20110201795-A1 | Methods of Producing C-Aryl Glucoside SGLT2 Inhibitors | SLC5A2, SLC5A1, GCG | ALDH1A1 1400/4885TSHR 3941/4885TDP1 4808/4885 |
| US-20160185717-A1 | COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | MRPL21, CFTR, ABCB11 | ALDH1A1 838/4885TSHR 1943/4885TDP1 4210/4885 |
| US-20050131224-A1 | Method for preparing radiolabeled thymidine | TYMP, TYMS, DUT | ALDH1A1 2386/4885TSHR 583/4885TDP1 219/4885 |
| US-20040138439-A1 | inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2), and more particularly to a process of producing such compounds, for example 1-C-(substituted diphenylmethane-3-yl)- beta -D-glucopyranose | SLC5A1, SLC5A2, SLC2A1 | ALDH1A1 1616/4885TSHR 4376/4885TDP1 4610/4885 |
| US-20140243517-A1 | METHODS OF PRODUCING C-ARYL GLUCOSIDE SGLT2 INHIBITORS | SLC5A2, SLC5A1, GCG | ALDH1A1 1400/4885TSHR 3941/4885TDP1 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.